Japanese 
English 
TOKYO, Japan, October 17, 2025: — PRISM BioLab announces that Eisai Co., Ltd. will present clinical trial results and biomarker exploration data for E7386, co-created by PRISM BioLab and Eisai, in combination with lenvatinib mesylate, at the European Society for Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from October 17 to 22, 2025....
アーカイブ: ニュース
PRISM BioLab、PepMetics®化合物の新規二環性化合物の特許取得のお知らせ
PRISM Biolabは、2025年9月30日に、新規化合物群に関する特許を取得したことをお知らせします。
Servier社との共同研究及び導出契約の終了に関するお知らせ
We would like to announce that PRISM BioLab and Servier have mutually agreed to terminate the collaboration and licensing agreement previously established between the two companies. For more details, please click here (English language PDF).
Eli Lilly and Company 社との共同研究及び導出契約の終了に関するお知らせ
この度、当社とEli Lilly and Company社は、両社間で締結されている共同研究及び導出契約を終了することとなりましたので、お知らせいたします。
PRISM BioLab、PepMetics®技術ライブラリー化合物特許取得のお知らせ
PRISM Biolabは、2025年5月30日に、新規化合物群に関する特許を取得したことをお知らせします。
PRISM BioLabとエーザイが共同創出したE7386、エーザイが米国臨床腫瘍学会（ASCO）年次総会にて臨床試験結果を発表
TOKYO, Japan, 23 May 2025: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386, created through collaboration research with Eisai Co., Ltd. , and Lenvatinib mesylate (“lenvatinib”) will be presented by...
個人投資家向けIRセミナー参加のお知らせ
CEO Dai Takehara will participate in the “103rd IR Seminar for Individual Investors” hosted by Logmi Finance on Saturday, May 17, 2025. As a company committed to sustainable growth and corporate value enhancement, we actively promote dialogue with shareholders and investors through our proactive IR activities. We will continue our efforts to communicate information and...
蛋白質間相互作用の制御を可能にするPepMetics技術
MEDCHEM NEWS, 35(2), 75-80 (2025) Hajime Takashima, Research and Development Department, PRISM BioLab Co., Ltd. https://www.jstage.jst.go.jp/article/medchem/35/2/35_75/_article/-char/en
日経バイオテク掲載のお知らせ
Nikkei Biotech has published an interview with our CEO Dai Takehara, and our Director/Head of R&D Dr. Park. Special Feature: Peptide Drug Discovery Finally Taking Off “The Future of PPI Drug Discovery: A Conversation with PRISM BioLab CEO Dai Takehara” https://bio.nikkeibp.co.jp/atcl/news/p1/25/04/15/13203/
日本経済新聞掲載のお知らせ
PRISM BioLab has been featured in The Nikkei (Nihon Keizai Shimbun). “PRISM BioLab and AI Drug Discovery Startup Partner for Efficient Drug Development” https://www.nikkei.com/article/DGXZQOUC1173U0R10C25A4000000/